09887 維立志博－Ｂ
LEADS BIOLABS-B
LEADS BIOLABS-B
| Listing Date | 2025/07/25 |
| Listing Price | 35.000 |
Subscription Result
- Subscription Rate3,494.78x
- Guarantee One Lot Size400 lot
- One Lot Success Rate0.27%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Nanjing Leads Biolabs Co. was founded in 2012, it is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases.
--
The Group has internally developed its Core Product, LBL-024, a registrational-stage PD-L1 and 4-1BB dual-targeting bispecific antibody. In addition, the Group has also internally discovered: five other clinical-stage candidates, and eight additional pre-clinical stage candidates.
--
The Group has established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. The Group has also developed including LeadsBodyTM platform (a CD3 T-cell engager platform), X-bodyTM platform (a 4-1BB engager platform), and several other bispecific antibody and fusion protein platforms.
--
As of July 11, 2025, the Group owned seven issued patents in China, six issued patents in the U.S., nine issued patents in other jurisdictions, and 61 patent applications. The Group had only one customer, BeiGene.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 36.86M H shares |
| No. of International Offer Shares | 20.84M H shares |
| No. of HK Offer Shares | 16.03M H shares |
| Offer Price | $31.60 - $35.00 |
| Stock Code | 9887 |
| Sponsor(s) | Morgan Stanley Asia Limited, CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, CLSA Limited, CMB International Capital Limited, CCB International Capital Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Jul 17 (Thu) - noon, Jul 22 (Tue) |
| Price Determination Date | Jul 23 (Wed) |
| Result Announcement Date | On or before Jul 24 (Thu) |
| Result Announcement Date | On or before Jul 24 (Thu) |
| Result Announcement Date | On or before Jul 25 (Fri) |
| Dealings in Shares commence on | Jul 25, 2025. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $31.60 - $35.00 |
| Capitalization (H Shares) | 4.52B - 5.00B |
| NAV / share ($) | $6.10 - $6.65 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 33.3, the net proceeds raised would be HKD 967.70M, of which |
| 65% : Ｏngoing and planned clinical development and regulatory affairs of clinical-stage drug candidates |
| 15% : Advancement of preclinical assets, expansion of existing pipeline, as well as optimization of technology platforms |
| 10% : Upgrading manufacturing capacity for commercialization of drug candidates after approved for sale |
| 10% : Working capital |
IPO NEWS
| 25/07/2025 16:08 |
| {New Stock}LEADS BIOLABS-B(09887) ends up 91.71% at HK$67.1 |
| 25/07/2025 09:20 |
| {New Stock}LEADS BIOLABS-B opens up 106.86% at HK$72.4 |
| 24/07/2025 18:35 |
| {New Stock}LEADS BIOLABS-B ends up 100.14% on grey market |
| 24/07/2025 16:20 |
| {New Stock}LEADS BIOLABS-B up 90% at HK$66.5 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).